There is a phase II clinical trial that is specifically designed to look at the effectiveness of nivolumab in patients with IDH1 or IDH2 hypermutated gliomas (hypermutator phenotype) currently recruiting (NCT03718767). Here, IDH1 is linked to central nervous system cancer.